Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Simcere Pharmaceutical Group Ltd

Simcere Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.95
  • Today's Change-0.07 / -1.00%
  • Shares traded4.23m
  • 1 Year change+1.16%
  • Beta0.4345
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)6.93bn
  • Net income in HKD-1.21bn
  • Incorporated2015
  • Employees6.41k
  • Location
    Simcere Pharmaceutical Group LtdNo. 699-18, Xuanwu Road, Xuanwu DistrictNANJING ChinaCHN
  • Websitehttp://www.simcere.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AIM Vaccine Co Ltd1.29bn-1.30bn9.10bn1.56k--2.38--7.03-1.07-1.071.073.160.14620.63251.10796,494.10-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd457.20m-1.15bn10.25bn520.00--2.10--22.42-3.57-3.571.4215.020.07565.233.221,058,327.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Luye Pharma Group Ltd6.90bn841.60m10.50bn5.23k12.470.7386.201.520.22370.22371.833.780.2362.443.021,308,626.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
SSY Group Ltd6.47bn1.37bn11.15bn5.80k8.211.546.101.720.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Shanghai Henlius Biotech Inc6.16bn756.26m11.82bn3.55k15.674.2010.191.921.391.3911.295.180.57641.906.821,694,066.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
China Traditional Chinese Med Hldg CoLtd18.79bn1.00bn11.99bn17.72k11.960.51345.240.63780.1990.1993.734.640.4531.541.821,086,100.002.624.604.017.0749.8657.075.779.771.517.390.180817.3526.699.9968.11-2.24-12.75--
3SBio Inc9.20bn1.81bn13.97bn5.61k7.840.88896.211.520.74370.74373.786.560.35751.526.871,700,070.007.257.4410.269.2985.9482.9120.2721.501.57141.550.1998--13.8411.26-19.133.948.78--
Grand Pharmaceutical Group Ltd10.59bn2.41bn16.19bn10.78k6.621.035.631.530.68850.68853.034.430.44723.624.541,005,064.0010.2510.0914.2114.0159.0061.9722.9222.351.09--0.223226.9410.1212.06-9.5921.415.6924.77
Simcere Pharmaceutical Group Ltd6.93bn-1.21bn17.74bn6.41k--2.37--2.56-0.4604-0.46042.692.970.51982.192.64985,844.90-9.0410.17-11.7115.6077.0278.82-17.4017.501.880.47210.146146.684.497.92-23.22-0.521323.93--
China Medical System Holdings Ltd7.66bn1.52bn19.00bn5.78k12.531.0810.792.480.62160.62163.137.190.3842.895.651,343,944.007.5118.448.5321.1474.1375.4719.5634.263.97--0.066740.14-12.438.08-26.335.3538.695.19
The United Laboratories Intl. Hldgs Ltd.15.30bn3.18bn19.19bn15.00k6.041.305.051.251.751.758.428.130.65783.305.671,020,171.0013.657.8920.7212.6446.1544.1720.7512.731.72--0.153228.9921.2212.8470.8531.6624.1946.04
Zai Lab Ltd2.51bn-2.32bn23.81bn2.18k--4.29--9.49-2.39-2.392.585.580.30833.045.52---28.50-37.72-34.92-42.7263.1764.75-92.44-282.443.29--0.0908--24.03360.0324.51---3.45--
HUTCHMED (China) Ltd4.75bn-326.19m24.75bn1.97k--4.30--5.21-0.3881-0.38815.506.600.47757.104.152,387,889.00-3.30-14.35-4.65-20.4341.6736.57-6.91-31.442.68--0.0984--96.5231.38127.93--38.65--
Data as of Nov 01 2024. Currency figures normalised to Simcere Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.54%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 30 Jun 202424.51m0.97%
The Vanguard Group, Inc.as of 02 Oct 202423.10m0.91%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202415.84m0.63%
Principal Global Investors (Hong Kong) Ltd.as of 30 Jun 202415.30m0.61%
Dimensional Fund Advisors LPas of 03 Oct 202414.19m0.56%
GF Fund Management Co., Ltd.as of 30 Jun 202412.70m0.50%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 202410.07m0.40%
BlackRock Fund Advisorsas of 03 Oct 20248.74m0.35%
China Asset Management Co., Ltd.as of 30 Jun 20248.00m0.32%
Essence Fund Co., Ltd.as of 30 Jun 20247.62m0.30%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.